Need for increased awareness and evidence-based therapies for patients hospitalized for heart failure

JAMA

Volumn 310, Issue 19, 2013, Pages 2035-2036

  Butler, Javed ^a   Fonarow, Gregg C ^b   Gheorghiade, Mihai ^c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEART INFARCTION; AWARENESS; CANCER RISK; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COST OF ILLNESS; EVIDENCE BASED PRACTICE; HEART FAILURE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; MEDICARE; MORBIDITY; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; SELF CARE; SHORT SURVEY;

EID: 84887921318     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.282815     Document Type: Short Survey

References (10)

1. Go AS, Mozaffarian D, Roger VL, et al American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6-e245.
2. Gheorghiade M, Böhm M, Greene SJ, et al ASTRONAUT Investigators and Coordinators. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA. 2013;309(11):1125-1135.
3. Chen J, Normand SL, Wang Y, Krumholz HM. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA. 2011;306(15):1669-1678.
4. Gheorghiade M, Abraham WT, Albert NM, et al OPTIMIZE-HF Investigators and Coordinators. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006;296(18):2217-2226.
5. Gheorghiade M, Pang PS, Ambrosy AP, et al. A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. Heart Fail Rev. 2012;17(3):485-509.
6. Cancer facts & figures 2013. http://www.cancer.org/acs/groups/ content/@epidemiologysurveilance/documents/document/acspc-036845.pdf. Accessed October 28, 2013.
7. Allen LA, Yager JE, Funk MJ, et al. Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure. JAMA. 2008;299(21):2533-2542.
8. Heart Disease Facts and Statistics. http://www.cdc.gov/heartdisease/ statistics.htm. August 10, 2013.
9. Heidenreich PA, Albert NM, Allen LA, et al American Heart Association Advocacy Coordinating Committee; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Stroke Council. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606-619.
10. Bradley EH, Curry L, Horwitz LI, et al. Hospital strategies associated with 30-day readmission rates for patients with heart failure. Circ Cardiovasc Qual Outcomes. 2013;6(4):444-450.